[go: up one dir, main page]

BRPI1014070B8 - processos para a produção de inibidor de dipeptidil peptidase-iv e intermediário - Google Patents

processos para a produção de inibidor de dipeptidil peptidase-iv e intermediário

Info

Publication number
BRPI1014070B8
BRPI1014070B8 BRPI1014070A BRPI1014070A BRPI1014070B8 BR PI1014070 B8 BRPI1014070 B8 BR PI1014070B8 BR PI1014070 A BRPI1014070 A BR PI1014070A BR PI1014070 A BRPI1014070 A BR PI1014070A BR PI1014070 B8 BRPI1014070 B8 BR PI1014070B8
Authority
BR
Brazil
Prior art keywords
production
inhibitor
dipeptidyl peptidase
processes
present
Prior art date
Application number
BRPI1014070A
Other languages
English (en)
Inventor
Jae Kim Heung
Joo Shim Hyun
Pil Min Jong
Yoo Moohi
Hyun Yoon Tae
Young Kwak Woo
Original Assignee
Dong A Pharm Co Ltd
Dong A Socio Holdings Co Ltd
Dong A St Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd, Dong A Socio Holdings Co Ltd, Dong A St Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of BRPI1014070A2 publication Critical patent/BRPI1014070A2/pt
Publication of BRPI1014070B1 publication Critical patent/BRPI1014070B1/pt
Publication of BRPI1014070B8 publication Critical patent/BRPI1014070B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/16—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms
    • C07D203/18—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carboxylic acids, or by sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

processo aprimorado para a produção de inibidor de dipeptidil peptidase-iv e intermediário. a presente invenção refere-se a um processo aprimorado para a produção de inibidor de dipeptidil peptidase-iv e intermediário. a presente invenção permite a redução dos custos de produção através da reação de reagentes de baixo custo, aumenta o rendimento e pode ser adaptada produção em massa.
BRPI1014070A 2009-03-30 2010-03-30 processos para a produção de inibidor de dipeptidil peptidase-iv e intermediário BRPI1014070B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2009-0027106 2009-03-30
KR20090027106 2009-03-30
PCT/KR2010/001948 WO2010114292A2 (ko) 2009-03-30 2010-03-30 디펩티딜 펩티다아제-ⅳ 저해제 및 중간체의 개량된 제조방법

Publications (3)

Publication Number Publication Date
BRPI1014070A2 BRPI1014070A2 (pt) 2016-04-12
BRPI1014070B1 BRPI1014070B1 (pt) 2020-10-20
BRPI1014070B8 true BRPI1014070B8 (pt) 2021-05-25

Family

ID=42828846

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014070A BRPI1014070B8 (pt) 2009-03-30 2010-03-30 processos para a produção de inibidor de dipeptidil peptidase-iv e intermediário

Country Status (16)

Country Link
US (1) US8598347B2 (pt)
EP (2) EP2415754A4 (pt)
JP (1) JP5475864B2 (pt)
KR (1) KR101152898B1 (pt)
CN (1) CN102378752B (pt)
AU (1) AU2010232086B2 (pt)
BR (1) BRPI1014070B8 (pt)
CA (1) CA2756915C (pt)
ES (1) ES2571443T3 (pt)
HU (1) HUE029168T2 (pt)
IL (1) IL215289A (pt)
MX (1) MX2011010205A (pt)
NZ (1) NZ595543A (pt)
RU (1) RU2498976C9 (pt)
SG (1) SG174973A1 (pt)
WO (1) WO2010114292A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011010204A (es) * 2009-03-30 2011-10-17 Dong A Pharm Co Ltd Procedimiento mejorado para preparar inhibidor de dipeptidil peptidasa-iv e intermediario.
CN104257437B (zh) * 2014-10-20 2016-01-06 谢杨 一种动物脊髓损伤造模装置
KR101709127B1 (ko) * 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
CN105017081B (zh) * 2015-07-08 2017-03-08 和鼎（南京）医药技术有限公司 一种西他列汀中间体的制备方法
EP3807894A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for lowering blood sugar with a dipeptidyl peptidase-4 inhibitor pharmaceutical composition
CN116554060B (zh) * 2023-05-23 2024-11-15 江苏八巨药业有限公司 一种Boc-(R)-3-氨基-4-(2,4,5-三氟苯基)丁酸的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781221B1 (fr) * 1998-07-17 2000-10-13 Lafon Labor Piperazinones substituees en alpha
KR20000065816A (ko) * 1999-04-09 2000-11-15 성재갑 파라 및/또는 메타-치환 시아노페닐알라닌 유도체의 새로운 합성방법
WO2003000181A2 (en) 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
JP2005526811A (ja) 2002-03-25 2005-09-08 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療または予防用β−アミノ複素環式ジペプチジルペプチダーゼ阻害剤
ATE451369T1 (de) 2002-07-15 2009-12-15 Merck & Co Inc Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
AU2003275404A1 (en) 2002-10-07 2004-05-04 Merck & Co., Inc. Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors
WO2004083173A2 (en) 2003-03-18 2004-09-30 Merck & Co., Inc. Ketopiperazine derivatives as bradykinin antagonists
WO2004087650A2 (en) 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
US7259160B2 (en) * 2003-07-31 2007-08-21 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006098342A1 (en) 2005-03-16 2006-09-21 Astellas Pharma Inc. Piperazinyl compounds
EP1702916A1 (en) 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH DPP-IV inhibitors
WO2007063928A1 (ja) 2005-11-30 2007-06-07 Toray Industries, Inc. 新規な非環状アミンカルボキシアミド誘導体及びその塩
US20090156465A1 (en) 2005-12-30 2009-06-18 Sattigeri Jitendra A Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
WO2008028662A1 (en) 2006-09-07 2008-03-13 Santhera Pharmaceuticals (Schweiz) Ag N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment of type 2 diabetes mellitus
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
AU2008241692B2 (en) * 2007-04-19 2011-02-10 Dong-A Pharm. Co., Ltd. DPP-IV inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity
KR100904426B1 (ko) 2007-09-11 2009-06-26 주식회사 하이닉스반도체 내부 전압 생성 회로

Also Published As

Publication number Publication date
HUE029168T2 (hu) 2017-02-28
ES2571443T3 (es) 2016-05-25
EP2669266B1 (en) 2016-02-24
EP2415754A4 (en) 2012-08-22
IL215289A0 (en) 2011-11-30
US8598347B2 (en) 2013-12-03
CA2756915C (en) 2015-06-02
RU2011141209A (ru) 2013-05-10
RU2498976C9 (ru) 2014-02-27
WO2010114292A2 (ko) 2010-10-07
CN102378752B (zh) 2014-08-20
IL215289A (en) 2015-10-29
CN102378752A (zh) 2012-03-14
AU2010232086B2 (en) 2013-02-28
NZ595543A (en) 2013-05-31
HK1168086A1 (en) 2012-12-21
BRPI1014070B1 (pt) 2020-10-20
RU2498976C2 (ru) 2013-11-20
KR20100109493A (ko) 2010-10-08
KR101152898B1 (ko) 2012-06-05
US20120016126A1 (en) 2012-01-19
JP5475864B2 (ja) 2014-04-16
SG174973A1 (en) 2011-11-28
CA2756915A1 (en) 2010-10-07
WO2010114292A3 (ko) 2011-01-20
JP2012522045A (ja) 2012-09-20
BRPI1014070A2 (pt) 2016-04-12
EP2669266A1 (en) 2013-12-04
EP2415754A2 (en) 2012-02-08
AU2010232086A1 (en) 2011-11-03
MX2011010205A (es) 2011-10-17

Similar Documents

Publication Publication Date Title
BRPI0920029A2 (pt) processo para produção de ferro diretamente reduzido
BR112012011689B8 (pt) processo para a produção de etexilato de dabigatran e compostos intermediários
BRPI0519624A2 (pt) processos para produÇço de ansamitocinas
BRPI1014070B8 (pt) processos para a produção de inibidor de dipeptidil peptidase-iv e intermediário
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
BRPI0921408A2 (pt) processo para a fabricação de (r)-2-acetamido-n-benzil-3-metoxipropion-amida (i) opticamente pura.
BR112012006031A2 (pt) processo para preparação de compostos azabicíclicos.
BRPI0910689A2 (pt) processo de síntese de rna por via química
BR112012027051A2 (pt) processo de oxidação biocatalítica com produto gênico alkl.
BRPI0919624A2 (pt) processo de descontaminação de gás de síntese.
BR112012003615A2 (pt) processo para a produção de butadieno
BRPI1007595A2 (pt) Processo aperfeiçoado de pré-tratamento de biomassa.
BRPI0908007A2 (pt) processo em refinaria
BRPI0910916A2 (pt) Processo para a produção de um dianidroaçúcar
BRPI0923822A2 (pt) Processo para a produção livre de células de produtos químicos
BR112012029925A2 (pt) pedra-pomes granulada, bem como processo para produção de pedra-pomes granulada
BR112012000210A2 (pt) processo para a produção de heterodímeoros de ácido glutâmico.
BRPI0914788A2 (pt) Processo para a produção de um produto intermediário de etexilato de dabigatran
DE602007011139D1 (de) Herstellungsverfahren für organische Säure
BRPI0909004A2 (pt) Processo para produção de biogás
BRPI0921736A2 (pt) processo para a fabricação de p4o6 com alto rendimento
BR112013026660A2 (pt) métodos ou processos para produção de depsipeptídeos macrocíclicos e intermediários
BRPI0920689A2 (pt) processo para produção de cumeno
BRPI0920435A2 (pt) processo para produzir gás de síntese de amônia.
IT1397745B1 (it) Processo integrato di purificazione di acque reflue di raffineria, contenenti prevalentemente ammoniaca ed acido solfidrico, e di gas acidi contenenti prevalentemente acido solfidrico.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: DONG-A SOCIO HOLDINGS CO., LTD. (KR)

B25A Requested transfer of rights approved

Owner name: DONG-A ST CO., LTD. (KR)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF